Diamonds in the Rough
Cross-referencing fundamental value against technical exhaustion to isolate beaten-down ARKG constituents that screen cheap and oversold. The bottom-right quadrant — high earnings yield, low RSI — is the prime hunting ground, especially where money flow (MFI) shows quiet accumulation despite the falling price.
Educational screen, not investment advice. “Diamond” classification is a mechanical valuation-vs-RSI split around the cohort median earnings yield and an RSI of 50.
Alpha Quadrant — Valuation × Technical Exhaustion
X = earnings yield (cheaper right) · Y = RSI 14 (more oversold lower) · bubble = market cap · color = money flow.
Diamond Candidates
Ranked by a composite of earnings yield, ROIC, oversold RSI, recent weakness, and improving money flow.
| # | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | VCYT | Veracyte, Inc. | 33.3 | 1.90% | 0.13 | 43 | -23.78% | 45 | safe |
| 2 | ILMN | Illumina Inc | 24.9 | 2.33% | 0.33 | 72 | +15.77% | 65 | safe |
| 3 | CERS | Cerus Corp | 24.2 | -0.54% | -0.04 | 49 | -8.11% | 77 | distress |
| 4 | LLY | Eli Lilly & Co. | 23.5 | 2.74% | 0.70 | 55 | +2.72% | 50 | safe |
| 5 | TXG | 10x Genomics, Inc. Class A Common Stock | 10.0 | -0.78% | -0.08 | 71 | +39.63% | 66 | safe |
| 6 | TWST | Twist Bioscience Corporation Common Stock | 10.0 | -1.54% | -0.41 | 70 | +61.95% | 77 | safe |
| 7 | TEM | Tempus AI, Inc. Class A Common Stock | 10.0 | -1.99% | -0.29 | 66 | +56.92% | 69 | safe |
| 8 | CRSP | CRISPR Therapeutics AG | 10.0 | -11.43% | -0.34 | 66 | +27.78% | 77 | safe |
| 9 | PSNL | Personalis, Inc. Common Stock | 10.0 | -5.10% | -0.32 | 67 | +44.35% | 78 | safe |
| 10 | NTRA | Natera, Inc. Common Stock | 10.0 | -0.67% | -0.24 | 72 | +27.62% | 67 | safe |
| 11 | CMPS | COMPASS Pathways Plc American Depository Shares | 10.0 | -11.30% | -- | 64 | +32.15% | 74 | distress |
| 12 | NRIX | Nurix Therapeutics, Inc. Common stock | 10.0 | -10.74% | -0.53 | 63 | +13.95% | 66 | safe |
| 13 | SDGR | Schrodinger, Inc. Common Stock | 10.0 | -14.95% | -0.49 | 67 | +31.51% | 77 | grey |
| 14 | WGS | GeneDx Holdings Corp. Class A Common Stock | 10.0 | -0.51% | -0.06 | 69 | +47.22% | 69 | safe |
| 15 | IONS | Ionis Pharmaceuticals, Inc. Common Stock | 10.0 | -3.12% | -0.20 | 61 | +11.67% | 82 | safe |
Short-Squeeze Watch
Constituents with the highest composite squeeze score — heavy short interest meeting price support.
| # | |||||||
|---|---|---|---|---|---|---|---|
| 1 | PRME | Prime Medicine, Inc. Common Stock | 92.7 | 34.63% | 12.90 | +24.92% | critical |
| 2 | ARCT | Arcturus Therapeutics Holdings Inc. Common Stock | 89.3 | 31.64% | 16.52 | +172.07% | critical |
| 3 | BEAM | Beam Therapeutics Inc. Common Stock | 89.0 | 29.47% | 11.31 | +21.93% | critical |
| 4 | NTLA | Intellia Therapeutics, Inc | 86.1 | 38.36% | 11.96 | +22.93% | critical |
| 5 | TWST | Twist Bioscience Corporation Common Stock | 85.2 | 26.26% | 11.12 | +61.95% | critical |
| 6 | ABSI | Absci Corporation Common Stock | 84.5 | 35.27% | 11.65 | +23.38% | critical |
| 7 | GENB | Generate Biomedicines, Inc. Common Stock | 82.1 | 12.70% | 15.25 | +49.41% | critical |
| 8 | WGS | GeneDx Holdings Corp. Class A Common Stock | 80.8 | 26.14% | 8.58 | +47.22% | critical |
| 9 | RXRX | Recursion Pharmaceuticals, Inc. Class A Common Stock | 80.3 | 41.64% | 9.31 | +17.49% | critical |
| 10 | CRSP | CRISPR Therapeutics AG | 79.8 | 22.75% | 11.52 | +27.78% | critical |
| 11 | SDGR | Schrodinger, Inc. Common Stock | 75.8 | 21.01% | 12.83 | +31.51% | critical |
| 12 | PACB | Pacific Biosciences of California, Inc. | 73.2 | 19.64% | 7.35 | +11.76% | high |
Market cap, valuation, and short-interest metrics are joined to the latest ARKG holdings snapshot; each ticker links to its full quote and analysis page.